|
Market Cap (2-Jul) $2,324,063,488 (333rd) |
Close (30-Jun) $1.14 |
Volume (30-Jun) 2,606,681 |
Shortsold (19-Jun) 79,324,475 (6.21%) (26th) |
|
52w High $3.37 |
52w Low $0.88 |
P/E 454.55 |
EPS -0.13 |
A news article has been posted about Mesoblast on the AFR. The article was published around , on 28 February 2021 at 5:00pm.
In their review of Mesoblast’s interim results – released at 7pm on Friday night – the auditors say “material uncertainty exists that may cast significant doubt on the group’s ability to continue as a going concern”.
Read ArticleMSB was $2.46 at the close of trade on 26 February 2021
| Recent Articles about ASX:MSB | |
|---|---|
| 31-Dec | Zip Co, Mesoblast among ASX's best performers in 2024
canberratimes.com.au |
| 31-Dec | Why DroneShield, Invictus Energy, Mesoblast, Weebit Nano shares are rising today
msn.com |
| 31-Dec | Mesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall
seekingalpha.com |
| 31-Dec | Remestemcel-L by Mesoblast for Crohn’s Disease (Regional Enteritis): Likelihood of Approval
pharmaceutical-technology.com |
| 27-Dec | Why Bowen Coal, Droneshield, Mesoblast, and St Barbara shares are racing higher today
msn.com |
| 27-Dec | Mesoblast Sees Major Change in Substantial Holding
markets.businessinsider.com |
| 25-Dec | Mesoblast (NASDAQ:MESO) Cut to Hold at Jefferies Financial Group
etfdailynews.com |
| 25-Dec | Mesoblast (NASDAQ:MESO) Shares Gap Up – Here’s Why
etfdailynews.com |
| 24-Dec | Mesoblast scores first US nod for mesenchymal stromal cell therapy
bioworld.com |
| 23-Dec | Mesoblast Director Increases Share Holdings Significantly
nasdaq.com |
| Tracked |
Find all articles about Mesoblast, including others on the AFR, on the media page.
You must be logged in to post a reply.
Mesoblast 